Value of Screening MRI Brain in Stage IV Non-small Cell Lung Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Medical Center Groningen
About this trial
Patients with newly diagnosed stage IV non-oncogene addicted NSCLC, who are fit for systemic treatment and don't have any symptoms of brain disease will undergo an MRI of the brain to screen for brain disease.
Eligibility criteria
Qualifiers
Histologically or cytologically confirmed stage IV metastatic NSCLC, not amenable to curative treatment.
Fit for systemic treatment (PS 0-2) according to standard of care.
No symptoms of brain disease disease assessed according to standard clinical care by the thoracic oncologist.
Disqualifiers
Prior/concomitant therapy for stage IV disease.
Oncogenic diver mutation (e.g. EGFR, ALK, ROS1, RET, MET, and BRAF) with approved targeted treatment.
Contraindications for MRI scan with contrast as per standard of care protocol of the institution.
Trial design
Treatments tested in this trial
- MRI
Treatment groups
100 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov